Overview

Oxidative Stress and Oxysterols Profiling in Patients With Carotid Revascularization

Status:
Completed

Trial end date:
2014-12-01

Target enrollment:
0

Participant gender:
All

Summary

The combination of aspirin and dipyridamole, two antiplatelet drugs, is approved in Italy for the secondary prevention of cerebral embolism in patients with carotid atherosclerosis. Besides antiplatelet activity, Dipyridamole has additional pharmacological action, including vasodilation and antioxidant properties. A role for oxidative stress has been suggested in acute cerebrovascular disease. In this study the investigators want to test the in vivo antioxidant activity of dipyridamole in patients who are candidate to take the drug under approved conditions of the Italian Drug Regulation Agency, i.e. secondary prevention of TIA/Stroke in patinets with carotid stenosis (>= 70%). To test the hypothesis that dipyridamole acts as antioxidant in vivo, oxysterols (products of cholesterol autoxidation) and vitamin E are measured in plasma before and after 6 months therapy after carotid endoarterectomy. Since dipyridamole is approved as combination preparation with aspirin, a control group of patients taking aspirin alone is enrolled. Outcome measures: plasma biomarkers (oxysterols and vitamin E) change at two time points: baseline and 6-months therapy.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

University of Roma La Sapienza

Collaborator:

Civic Hospital, Italy

Treatments:

Aspirin
Dipyridamole

Criteria

Inclusion Criteria:

- Patients with carotid atherosclerosis eligible for carotid endoarterectomy (stenosis
>= 70%) with previous TIA or Stroke

Exclusion Criteria:

- Congestive heart failure, chronic liver disease, chronic kidney disease (GFR < 60%),
cancer, use of antioxidant supplements in the previous 3 months, autoimmune diseases